BIOCURE TECHNOLOGY INC. (1WH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIOCURE TECHNOLOGY INC. (1WH) has a cash flow conversion efficiency ratio of -0.005x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-8.28K ≈ $-9.68K USD) by net assets (€1.58 Million ≈ $1.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of BIOCURE TECHNOLOGY INC. to measure how much of total assets are equity-financed.
BIOCURE TECHNOLOGY INC. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BIOCURE TECHNOLOGY INC. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
BIOCURE TECHNOLOGY INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIOCURE TECHNOLOGY INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rare Foods Australia Ltd
AU:RFA
|
-0.026x |
|
EnSilica PLC
LSE:ENSI
|
0.203x |
|
International Frontier Resources Corporation
V:IFR
|
0.017x |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
-0.001x |
|
Satis Group S.A.
WAR:STS
|
0.000x |
|
Tearlach Resources Ltd
V:TEA
|
-0.043x |
|
Queste Communications Ltd
AU:QUE
|
-0.039x |
|
Argo Blockchain PLC ADR
NASDAQ:ARBK
|
-0.930x |
Annual Cash Flow Conversion Efficiency for BIOCURE TECHNOLOGY INC. (2021–2025)
The table below shows the annual cash flow conversion efficiency of BIOCURE TECHNOLOGY INC. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 1WH market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.58 Million ≈ $1.84 Million |
€-76.52K ≈ $-89.46K |
-0.049x | -574.70% |
| 2024-12-31 | €1.34 Million ≈ $1.57 Million |
€13.71K ≈ $16.03K |
0.010x | +107.55% |
| 2023-12-31 | €1.60 Million ≈ $1.87 Million |
€-217.13K ≈ $-253.84K |
-0.135x | -138.52% |
| 2022-12-31 | €-2.33 Million ≈ $-2.72 Million |
€-818.38K ≈ $-956.77K |
0.352x | -72.34% |
| 2021-12-31 | €-852.32K ≈ $-996.45K |
€-1.08 Million ≈ $-1.27 Million |
1.271x | -- |
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more